July 17, 2020

July 17, 2020

'Toxic' Parking Fees; FDA Expands Trial Eligibility; Lung Screening in the Country

MedPage Today – July 16

Elevated levels of the pro-inflammatory protein interleukin-6 may identify patients at increased risk of severe side effects from chimeric antigen receptor T-cell therapy. (Moffitt Cancer Center, Clinical Cancer Research)


Rhea Law Joins Board of Lions Eye Institute for Transplant & Research

Tampa Bay Newswire – July 16

She serves on the Board of Directors of Tampa Electric Company, as well as the H. Lee Moffitt Cancer Center and Research Institute National Board of Advisors.


Moffitt tech exec named to federal advisory committee

St. Pete Catalyst – July 16

Dave Summitt, chief information security officer at Moffitt Cancer Center, has been selected for the Federal Communication Commission’s newly formed federal advisory committee, the Hospital Robocall Protection Group.


Study Identifies Factors That May Predict Toxicities in Patients Treated With CAR T-Cell Therapy

 ASCO Post – July 16

“Identifying which [patients treated with] CAR T-cell therapy may be more susceptible to those severe toxicities before therapy could allow us to better tailor their care to mediate or reduce those adverse reactions,” said corresponding study author Marco Davila, MD, PhD, Associate Member of the Blood and Marrow Transplant and Cellular Immunotherapy Department and Medical Director of Cell Therapies at the H. Lee Moffitt Cancer Center & Research Institute.


C-level Moffitt executive chosen for FCC committee on robocalls 

Tampa Bay Business Journal - July 16

Dave Summitt, the chief information security officer of Moffitt Cancer Center, has been named to the Hospital Robocall Protection Group, a Federal Communications Commission advisory committee on robocalls, where he will serve as chairperson.


A miraculous journey: USF student survives stage four cancer

The Oracle – July 16

Fragello said her life was normal prior to December 2019, and she had never experienced a terminal illness or disability. Cancer was hardly ever prevalent in her life until she began volunteering at the H. Lee Moffitt Cancer Center & Research Institute.


Dr. Ahmed on Key Strategies for Managing Breast Cancer Brain Metastases

OncLive – July 15

Kamran A. Ahmed, MD, an assistant member in the Department of Radiation Oncology and the Department of Immunology at Moffitt Cancer Center, and an assistant professor in the Department of Oncologic Sciences at the University of South Florida, discusses key strategies to manage patients with breast cancer and brain metastases.


Han Highlights the Need for Personalized Treatment in HER2+ Early-Stage Breast Cancer

OncLive – July 15

In an interview with OncLive, as part of the virtual Institutional Perspectives in Cancer™ on Breast Cancer, Han, a medical oncologist and research director of Breast Oncology at Moffitt Cancer Center, further discussed ongoing clinical trials within the field of HER2-positive breast cancer and the future of personalized treatment for this patient population.


Dr. Czerniecki on Treatment Options for Patients With HER2+ Brain Metastases

OncLive – July 15

Brian Czerniecki, MD, PhD, chair and senior member, Department of Breast Oncology at Moffitt Cancer Center, discusses treatment options for patients with HER2-positive breast cancer who have brain metastases.


Moffitt Researchers Identify Factors to Predict Severe Toxicities in CAR T Patients

Newswise – July 15

In a new study published in Clinical Cancer Research, Moffitt Cancer Center researchers identify possible factors that could help physicians know if patients are at higher risk for severe adverse events before they receive CAR T therapy. Also posted to ScienceMag and Micro-Biology.


FCC Announces Meeting of Hospital Robocall Protection Group

ACA International – July 15

Members include: Chair: Paul D. Summitt, chief information security Officer of the Moffitt Cancer Center


Sam Shares Strategizes for Providing Optimal Care to Geriatric Patients With Cancer During the COVID-19 Crisis

OncLive – July 14

In an interview with OncLive during the Institutional Perspectives in Cancer program, Sam, a hematologist and oncologist and an assistant member in the Department of Individualized Cancer Management/Senior Adult Oncology Program at Moffitt Cancer Center, highlighted strategies to prevent the spread of COVID-19 in geriatric patients with cancer and shared advice on how to overcome unique challenges faced in the care of this population.


Moffitt Cancer Center CISO to chair FCC's new hospital robocalls protection group

Becker’s Hospital Review – July 14

FCC Chairman Ajit Pai designated Tampa, Fla.-based Moffitt Cancer Center Chief Information Security Officer Dave Summitt to chair the Hospital Robocall Protection Group, which will hold its first meeting on July 27. 


Phase 3 Data With Eprenetapopt Plus Azacitidine Anticipated in High-Risk MDS/AML

OncLive – July 14

In an interview with OncLive, Sallman, an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center, discussed the combination of eprenetapopt and azacitidine as a treatment for high-risk patients with TP53-mutant MDS and AML.


Real-world CAR T-cell therapy as safe, effective as in clinical trial setting

Healio – July 14

“The issue with clinical trials is that they often are very highly selective,” Michael D. Jain, MD, PhD, assistant member in the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer Center, told Healio.


Dual inhibitor therapy may be safer for CLL patients, Moffitt study shows

News Medical – July 14

Moffitt Cancer Center researchers want to learn more about how this type of inhibitor works with the body's immune system to determine if there are ways to predict or mitigate associated adverse effects. Also posted to Newswise and EurekAlert.


FCC seeks RX for robocalls

Multichannel News – July 14

Commissioner Brendan Carr will represent the FCC and Commissioner Noah Joshua Phillips will represent the Federal Trade Commission. Officers will be Dave Summitt of the Moffitt Cancer Center, chairman; Patrick Halley of USTelecom, vice chair.  


Hatem Soliman, MD on The Rolf of 12-Chemokine #ASCO2020

OncologyTube – July 14

Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated with neoadjuvant chemotherapy.


Mysterious Melanoma

Pittsburgh Quarterly – Summer 2020

“We have trained a dozen people who have taken over melanoma programs at places such as UNC-Chapel Hill, Cleveland Clinic, Moffitt Cancer Center and MD Anderson [Cancer Center].”


Initiative seeks to educate providers, improve care for LGBTQ+ patients with cancer

Healio – July 13

More importantly, we recruited Dr. Quinn, who came to us from Moffitt Cancer Center and had done these studies. The second paper she wrote looked at which cancers the LGBTQ+ population is at increased risk for and why.


15 health systems among top places to work in IT

Becker’s Hospital Review – July 13


The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs

Benzinga – July 11

Anixa Biosciences Inc ANIX said the European Patent Office has issued an Intention to Grant notice for the first European patent covering its novel CAR-T cancer treatment technology, which has been licensed from The Wistar Institute and is being developed at the Moffitt Cancer Center.



Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.